Preliminary experiences with Bio-Alcamid in HIV facial lipoatrophy

Dermatology. 2007;214(2):151-4. doi: 10.1159/000098575.

Abstract

Background: Highly active antiretroviral therapy for HIV-infected patients causes metabolic changes known as the lipodystrophy syndrome. Autologous fat injections, dermal fat grafts, malar implants and injected fillers have been reported as treatment options.

Objective: To evaluate the results of HIV-infected patients treated with Bio-Alcamid for facial lipoatrophy.

Methods and materials: Over a 3-year period, 13 HIV-infected patients with facial lipoatrophy had Bio-Alcamid injections for aesthetic purposes. The procedure was done under local anesthesia, and the amount of the injected material varied from 5 to 13 ml. Results were independently evaluated by patients and physicians.

Results: Most of the patients felt they had good to excellent results. Touch-ups were necessary for 2 patients; the added volume was 2-3 ml for each. No major complications were recorded. A small hematoma was noted in 1 patient. Overcorrection was attained in 2 cases, and some of the filler was removed at the patient's request.

Conclusion: One of the greatest advantages of this filler is that, although permanent, it can be removed easily. We consider Bio-Alcamid to be a safe and useful correcting tool for patients suffering from drug-induced facial lipoatrophy.

Publication types

  • Clinical Trial

MeSH terms

  • Acrylic Resins / administration & dosage
  • Acrylic Resins / therapeutic use*
  • Adult
  • Anti-Retroviral Agents / adverse effects
  • Anti-Retroviral Agents / therapeutic use
  • Face
  • Female
  • HIV Infections / drug therapy
  • HIV-Associated Lipodystrophy Syndrome / drug therapy*
  • HIV-Associated Lipodystrophy Syndrome / etiology
  • Humans
  • Injections, Subcutaneous
  • Male
  • Middle Aged
  • Treatment Outcome

Substances

  • Acrylic Resins
  • Anti-Retroviral Agents
  • Bio-Alcamid